Trial Profile
A Phase 2a, Partly Randomized, Open-label Trial to Investigate the Efficacy and Safety of an 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Subjects With Chronic Genotype 4 Hepatitis C Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2018
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms OSIRIS
- Sponsors Janssen-Cilag
- 18 Jan 2018 Results of pooled post-hoc analysis assessing impact of pharmacokinetic interaction between simeprevir and concomitant medications by using data from nine studies (SONET, OPTIMIST-1, OPTIMIST-2, COMMIT, GALAXY, OSIRIS, IMPACT, PLUTO and SATURN) published in the British Journal of Clinical Pharmacology.
- 26 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Nov 2015 Preliminary results of phase 2a part presented at The Liver Meeting 2015: 66th Annual Meeting of the American Association for the Study of Liver Diseases